Konstantin Koreyba
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Konstantin Koreyba has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Ekaterina Vladimirovna Silina
Institute of Biodesign and AI in medicine, I.M. Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow, Russia
4 shared publications - Victor Aleksandrovich Stupin
Department of Surgery, Pirogov Russian National Research Medical University, 117997 Moscow, Russia
4 shared publications - Natalia Evgenievna Manturova
N.I. Pirogov Russian National Research Medical University
3 shared publications D.K. Koreiba
Kazan National Research Technological University” - Institute of Innovation Management, Kazan, Russia
2 shared publications- Dmitry E. Tsyplakov
Kazan State Medical University
2 shared publications K A Koreyba
Kazan State Medical University, Kazan, Russia; «Diabetic Foot» Center, Kazan, Russia
2 shared publications
Latest Publications
- Open Access
- 9 October 2024
- Published by EDP Sciences in BIO Web of Conferences
- Vol. 130, 04003
Technical methods of improving the biomechanics of feet in people with diabetes
This article discusses the role of orthoses in correcting biomechanics for patients with diabetic foot syndrome. It also analyzes literature on the use of specialized orthopedic shoes to address biomechanical foot issues and complicated forms of diabetes mellitus. Today, the general requirements for designing orthopedic shoes for patients with diabetes are described: a stiff sole with an artificial cushion; a suitable volume, a wide sole, an insole without a memory function; a thermally changeable elastic material; a minimum number of seams in the lining; an elastic upper and lining material in the toe area of the shoe; an increased fullness and additional volume in the toe region of the shoe, an angle of the bevel at the toe end of the sole, and the ability to adjust the interior volume of the shoe by using a hard heel that is stabilized with additional softness from the lining, as well as a smooth, non-traumatic upper. Indications for orthopedic unloading in patients with diabetic foot syndrome are highlighted.There is a negative approach towards conservative methods of treating patients with diabetic feet, but amputation in these cases cannot be considered a positive outcome of treatment. Nearly 70 to 90 percent of ulcers in this patient group heal without amputation. Techniques using specially designed shoes are less expensive and more cost-effective than limb loss. The use of orthotic shoes in diabetic foot patients serves as a method of both correction and rehabilitation.
- 9 October 2024
- Published by EDP Sciences in BIO Web of Conferences
- Vol. 130, 04003
Open AccessTechnical methods of improving the biomechanics of feet in people with diabetes
This article discusses the role of orthoses in correcting biomechanics for patients with diabetic foot syndrome. It also analyzes literature on the use of specialized orthopedic shoes to address biomechanical foot issues and complicated forms of diabetes mellitus. Today, the general requirements for designing orthopedic shoes for patients with diabetes are described: a stiff sole with an artificial cushion; a suitable volume, a wide sole, an insole without a memory function; a thermally changeable elastic material; a minimum number of seams in the lining; an elastic upper and lining material in the toe area of the shoe; an increased fullness and additional volume in the toe region of the shoe, an angle of the bevel at the toe end of the sole, and the ability to adjust the interior volume of the shoe by using a hard heel that is stabilized with additional softness from the lining, as well as a smooth, non-traumatic upper. Indications for orthopedic unloading in patients with diabetic foot syndrome are highlighted.There is a negative approach towards conservative methods of treating patients with diabetic feet, but amputation in these cases cannot be considered a positive outcome of treatment. Nearly 70 to 90 percent of ulcers in this patient group heal without amputation. Techniques using specially designed shoes are less expensive and more cost-effective than limb loss. The use of orthotic shoes in diabetic foot patients serves as a method of both correction and rehabilitation.
- Open Access
- 5 January 2024
- Published by EDP Sciences in BIO Web of Conferences
- Vol. 84, 03011
RETRACTED: Study of the correlation dependence of complications in the organization of medication support when using cilostazol drugs as complex therapy for diabetic foot syndrome
See the retraction notice BIO Web of Conferences 84, 00001 (2024), https://doi.org/10.1051/bioconf/20248400001
- 5 January 2024
- Published by EDP Sciences in BIO Web of Conferences
- Vol. 84, 03011
Open AccessRETRACTED: Study of the correlation dependence of complications in the organization of medication support when using cilostazol drugs as complex therapy for diabetic foot syndrome
See the retraction notice BIO Web of Conferences 84, 00001 (2024), https://doi.org/10.1051/bioconf/20248400001
- Open Access
- 4 December 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (23) , 7202
Prognostic Value of Histological and Immunohistochemical Data in Diabetic Foot Ulcers
Diabetic foot ulcers are an extremely urgent medical and social problem throughout the world. The purpose of this study was to analyse the histological and immunohistochemical features of tissues and cells of different sections of wounds taken during the primary surgical treatment of chronic wounds in patients with diabetic foot syndrome with favourable and unfavourable outcomes. Material and methods. A clinical prospective observational study of the treatment outcomes of fifty-three patients with diabetic foot ulcers hospitalized twice in one specialized centre over the course of the year was conducted. The analysis of histological and immunohistochemical data of the tissues of the edges and the centre of the ulcer taken during the primary surgical treatment was performed. While performing histological analyses of wound tissues, special attention was given to the determination of cellular characteristics of leukocyte-necrotic masses, granulation tissue, and loose and dense connective tissue. Immunohistochemistry was performed using a set of monoclonal antibodies, allowing verification of neutrophilic leukocytes, fibroblasts, and endothelial cells. Results. Unfavourable outcomes (amputation, reamputation, death from cardiovascular diseases, nonhealing ulcer within a year) were registered in 52.8% of cases. Uniform distribution of neutrophils and endothelial cell fibroblasts in all parts of the wound was recorded in patients with a favourable outcome. An unfavourable outcome was predetermined by the uneven content of these cells with a significant increase in neutrophilic leukocytosis in the bottom of the wounds, as well as a significant decrease in the number of fibroblasts and endotheliocytes in the centre of the wounds. Conclusions: The datasets obtained during primary surgical treatment are extremely informative to predict the outcome of the treatment of diabetic foot ulcers and indicate more active surgical strategies with the potential to reduce the treatment time, increase its effectiveness, and eventually make the treatment cost-effective.
- 4 December 2022
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (23) , 7202
Open AccessPrognostic Value of Histological and Immunohistochemical Data in Diabetic Foot Ulcers
Diabetic foot ulcers are an extremely urgent medical and social problem throughout the world. The purpose of this study was to analyse the histological and immunohistochemical features of tissues and cells of different sections of wounds taken during the primary surgical treatment of chronic wounds in patients with diabetic foot syndrome with favourable and unfavourable outcomes. Material and methods. A clinical prospective observational study of the treatment outcomes of fifty-three patients with diabetic foot ulcers hospitalized twice in one specialized centre over the course of the year was conducted. The analysis of histological and immunohistochemical data of the tissues of the edges and the centre of the ulcer taken during the primary surgical treatment was performed. While performing histological analyses of wound tissues, special attention was given to the determination of cellular characteristics of leukocyte-necrotic masses, granulation tissue, and loose and dense connective tissue. Immunohistochemistry was performed using a set of monoclonal antibodies, allowing verification of neutrophilic leukocytes, fibroblasts, and endothelial cells. Results. Unfavourable outcomes (amputation, reamputation, death from cardiovascular diseases, nonhealing ulcer within a year) were registered in 52.8% of cases. Uniform distribution of neutrophils and endothelial cell fibroblasts in all parts of the wound was recorded in patients with a favourable outcome. An unfavourable outcome was predetermined by the uneven content of these cells with a significant increase in neutrophilic leukocytosis in the bottom of the wounds, as well as a significant decrease in the number of fibroblasts and endotheliocytes in the centre of the wounds. Conclusions: The datasets obtained during primary surgical treatment are extremely informative to predict the outcome of the treatment of diabetic foot ulcers and indicate more active surgical strategies with the potential to reduce the treatment time, increase its effectiveness, and eventually make the treatment cost-effective.
- 29 March 2022
- Published by Springer Nature in BioNanoScience
- Vol. 12 (2) , 693-699
Medical Imaging in Surgery for Diabetic Foot Syndrome: Clinical and Morphological Case Report
- 29 March 2022
- Published by Springer Nature in BioNanoScience
- Vol. 12 (2) , 693-699
Medical Imaging in Surgery for Diabetic Foot Syndrome: Clinical and Morphological Case Report
- Open Access
- 22 September 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (10) , 1534
Acute Skin Wounds Treated with Mesenchymal Stem Cells and Biopolymer Compositions Alone and in Combination: Evaluation of Agent Efficacy and Analysis of Healing Mechanisms
We studied the efficacy of using mesenchymal stem cells (MSC) and a polymeric compound (based on chitosan and cellulose with integrated cerium dioxide nanoparticles (PCCD)) in wound healing, and to compare the effects with various invasive and external drugs used for the same purpose. Two wounds were made on the backs of each of 112 Wistar rats, removing the skin. Eight groups were studied: Control_0—intact wounds; Control_ss—0.9% NaCl injections; MSC injections; Control_msc—intact wounds on the opposite side of the body from the MSC group; external application of the PCCD; external application of a combination of the drugs PCCD + MSC; DCh –ointment Dioxomethyltetrahydropyrimidine + Chloramphenicol; and DHCB—injections of a deproteinized hemoderivative of calf blood. After 14 days, we evaluated the state and size of the wounds, studied the level of microcirculation, performed a histological study, and identified and counted the different types of cells. The most effective remedy was combination PCCD + MSC. The treatments in the PCCD and MSC groups were more effective than in the DHCB and DCh groups. Invasive drugs and DCh slowed the regeneration process. DHCB did not affect the rate of healing for acute wounds without ischemia during the first week. The proven efficacy of developed polymeric compounds demonstrates the feasibility of further studies in clinical practice.
- 22 September 2021
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (10) , 1534
Open AccessAcute Skin Wounds Treated with Mesenchymal Stem Cells and Biopolymer Compositions Alone and in Combination: Evaluation of Agent Efficacy and Analysis of Healing Mechanisms
We studied the efficacy of using mesenchymal stem cells (MSC) and a polymeric compound (based on chitosan and cellulose with integrated cerium dioxide nanoparticles (PCCD)) in wound healing, and to compare the effects with various invasive and external drugs used for the same purpose. Two wounds were made on the backs of each of 112 Wistar rats, removing the skin. Eight groups were studied: Control_0—intact wounds; Control_ss—0.9% NaCl injections; MSC injections; Control_msc—intact wounds on the opposite side of the body from the MSC group; external application of the PCCD; external application of a combination of the drugs PCCD + MSC; DCh –ointment Dioxomethyltetrahydropyrimidine + Chloramphenicol; and DHCB—injections of a deproteinized hemoderivative of calf blood. After 14 days, we evaluated the state and size of the wounds, studied the level of microcirculation, performed a histological study, and identified and counted the different types of cells. The most effective remedy was combination PCCD + MSC. The treatments in the PCCD and MSC groups were more effective than in the DHCB and DCh groups. Invasive drugs and DCh slowed the regeneration process. DHCB did not affect the rate of healing for acute wounds without ischemia during the first week. The proven efficacy of developed polymeric compounds demonstrates the feasibility of further studies in clinical practice.
- Open Access
- 12 August 2021
- Published by MDPI AG in Pathophysiology
- Vol. 28 (3) , 355-372
Local and Remote Effects of Mesenchymal Stem Cell Administration on Skin Wound Regeneration
Wound healing is an important medical problem. We evaluated the efficacy of locally administered mesenchymal stem cells (MSCs) isolated from human umbilical cords on the dynamics of skin wound healing. The study was conducted on the backs of Wistar rats, where two square wounds were created by removing all layers of the skin. Four groups were studied in two series of experiments: (1) a Control_NaCl group (the wounds were injected with 0.9% NaCl solution) and a Control_0 group (intact wounds on the opposite side of the same rat’s back); (2) an MSC group (injected MSCs, local effect) and a Control_sc group (intact wounds on the opposite side of the back, remote MSC effect). The area and temperature of the wounds and the microcirculation of the wound edges were measured. Histological and morphometric studies were performed on days 3 and 7 after the wounds were created. The results showed that the injection trauma (Control_NaCl) slowed the regeneration process. In both MSC groups (unlike in either control group), we observed no increase in the area of the wounds; in addition, we observed inhibition of the inflammatory process and improved wound regeneration on days 1–3 in the remote group and days 1–5 in the local (injected) group. The MSC and Control_sc groups demonstrated improved microcirculation and suppression of leukocyte infiltration on day 3. On day 7, all the studied parameters of the wounds of the Control_0 group were the same as those of the wounds that received cell therapy, although in contrast to the results of the Control_ NaCl group, fibroblast proliferation was greater in the MSC and Control_sc groups. The dynamics of the size of the wounds were comparable for both local and remote application of MSCs. Thus, even a one-time application of MSCs was effective during the first 3–5 days after injury due to anti-inflammatory processes, which improved the regeneration process. Remote application of MSC, as opposed to direct injection, is advisable, especially in the case of multiple wounds, since the results were indistinguishable between the groups and injection trauma was shown to slow healing.
- 12 August 2021
- Published by MDPI AG in Pathophysiology
- Vol. 28 (3) , 355-372
Open AccessLocal and Remote Effects of Mesenchymal Stem Cell Administration on Skin Wound Regeneration
Wound healing is an important medical problem. We evaluated the efficacy of locally administered mesenchymal stem cells (MSCs) isolated from human umbilical cords on the dynamics of skin wound healing. The study was conducted on the backs of Wistar rats, where two square wounds were created by removing all layers of the skin. Four groups were studied in two series of experiments: (1) a Control_NaCl group (the wounds were injected with 0.9% NaCl solution) and a Control_0 group (intact wounds on the opposite side of the same rat’s back); (2) an MSC group (injected MSCs, local effect) and a Control_sc group (intact wounds on the opposite side of the back, remote MSC effect). The area and temperature of the wounds and the microcirculation of the wound edges were measured. Histological and morphometric studies were performed on days 3 and 7 after the wounds were created. The results showed that the injection trauma (Control_NaCl) slowed the regeneration process. In both MSC groups (unlike in either control group), we observed no increase in the area of the wounds; in addition, we observed inhibition of the inflammatory process and improved wound regeneration on days 1–3 in the remote group and days 1–5 in the local (injected) group. The MSC and Control_sc groups demonstrated improved microcirculation and suppression of leukocyte infiltration on day 3. On day 7, all the studied parameters of the wounds of the Control_0 group were the same as those of the wounds that received cell therapy, although in contrast to the results of the Control_ NaCl group, fibroblast proliferation was greater in the MSC and Control_sc groups. The dynamics of the size of the wounds were comparable for both local and remote application of MSCs. Thus, even a one-time application of MSCs was effective during the first 3–5 days after injury due to anti-inflammatory processes, which improved the regeneration process. Remote application of MSC, as opposed to direct injection, is advisable, especially in the case of multiple wounds, since the results were indistinguishable between the groups and injection trauma was shown to slow healing.
- Open Access
- 1 January 2020
- Published by LLC Russian Medical Journal in Russian Medical Inquiry
- Vol. 4 (7)
Antiplatelet agents in complex medication therapy in diabetic foot disease
The urgency of the problem concerning treatment of diabetic foot disease is due to the following reasons: pathogenesis ambiguity of this pathology, tendency to trophic defects relapse and increase in volume during the conservative treatment, resistance to conservative treatment, deterioration of the life quality of patients, treatment complexity and duration, and significant economic costs for treatment and rehabilitation. The patterns of complex medication therapy effects include insufficient evidence for most drugs, the lack of generally accepted regimens and the low efficacy of existing ones. Given the own experience and using a mathematical model, it was proved that the benefits of using Cilostazol as part of combined medication therapy regimen for patients with diabetic foot syndrome and stage IIA, IIB chronic limb ischemia according to the classification of Fontaine-Leriche-Pokrovsky. The need to adhere to National Clinical Guidelines was justified.KEYWORDS: diabetic foot syndrome, national clinical guidelines, disaggregants, pulse oximetry, chronic limb ischemia, oxygen saturation,outcomes assessment.FOR CITATION: Koreyba K.A. Antiplatelet agents in complex medication therapy in diabetic foot disease. Russian Medical Inquiry. 2020;4(7):457–462. DOI: 10.32364/2587-6821-2020-4-7-457-462.
- 1 January 2020
- Published by LLC Russian Medical Journal in Russian Medical Inquiry
- Vol. 4 (7)
Open AccessAntiplatelet agents in complex medication therapy in diabetic foot disease
The urgency of the problem concerning treatment of diabetic foot disease is due to the following reasons: pathogenesis ambiguity of this pathology, tendency to trophic defects relapse and increase in volume during the conservative treatment, resistance to conservative treatment, deterioration of the life quality of patients, treatment complexity and duration, and significant economic costs for treatment and rehabilitation. The patterns of complex medication therapy effects include insufficient evidence for most drugs, the lack of generally accepted regimens and the low efficacy of existing ones. Given the own experience and using a mathematical model, it was proved that the benefits of using Cilostazol as part of combined medication therapy regimen for patients with diabetic foot syndrome and stage IIA, IIB chronic limb ischemia according to the classification of Fontaine-Leriche-Pokrovsky. The need to adhere to National Clinical Guidelines was justified.KEYWORDS: diabetic foot syndrome, national clinical guidelines, disaggregants, pulse oximetry, chronic limb ischemia, oxygen saturation,outcomes assessment.FOR CITATION: Koreyba K.A. Antiplatelet agents in complex medication therapy in diabetic foot disease. Russian Medical Inquiry. 2020;4(7):457–462. DOI: 10.32364/2587-6821-2020-4-7-457-462.
- Open Access
- 15 April 2012
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 93 (2) , 368-369
The experience of using infusions of thrombolytic agents in the complex treatment of complicated forms of diabetic foot syndrome
The article presents the experience of using infusion thrombolytic agents in the complex therapy of patients with complicated diabetic foot syndrome. Presented was a vivid clinical case. This method made it possible to optimize the treatment of this group of patient.
- 15 April 2012
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 93 (2) , 368-369
Open AccessThe experience of using infusions of thrombolytic agents in the complex treatment of complicated forms of diabetic foot syndrome
The article presents the experience of using infusion thrombolytic agents in the complex therapy of patients with complicated diabetic foot syndrome. Presented was a vivid clinical case. This method made it possible to optimize the treatment of this group of patient.
- Open Access
- 15 April 2012
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 93 (2) , 370-371
Prostaglandin E1 in vascular reconstructive operations in patients with diabetic foot syndrome
The article presents the results of using prostaglandin E1 in the perioperative period in patients with diabetic foot syndrome who underwent reconstructive operations on the blood vessels of the lower extremities. This method made it possible to optimize the treatment of this group of patient.
- 15 April 2012
- Published by ECO-Vector LLC in Kazan medical journal
- Vol. 93 (2) , 370-371
Open AccessProstaglandin E1 in vascular reconstructive operations in patients with diabetic foot syndrome
The article presents the results of using prostaglandin E1 in the perioperative period in patients with diabetic foot syndrome who underwent reconstructive operations on the blood vessels of the lower extremities. This method made it possible to optimize the treatment of this group of patient.